Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease

26 de May de 2022

Check out this “hot off the press” article Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists (https://onlinelibrary.wiley.com/doi/10.1002/pds.5432) and the related earlier article No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968970/) with coauthors from SIGMA members Aarhus University, PHARMO Institute for Drug Outcomes Research and RTI Health Solutions.

https://onlinelibrary.wiley.com/doi/10.1002/pds.5432